Free Trial

AbCellera Biologics Q1 2023 Earnings Report

AbCellera Biologics logo
$3.03 -0.11 (-3.50%)
As of 02/21/2025 04:00 PM Eastern

AbCellera Biologics EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.12
Beat/Miss
Missed by -$0.02
One Year Ago EPS
$0.54

AbCellera Biologics Revenue Results

Actual Revenue
$12.20 million
Expected Revenue
$12.11 million
Beat/Miss
Beat by +$90.00 thousand
YoY Revenue Growth
-96.10%

AbCellera Biologics Announcement Details

Quarter
Q1 2023
Time
After Market Closes

ABCL Upcoming Earnings

AbCellera Biologics will be holding an earnings conference call on Thursday, February 27 at 5:00 PM Eastern. Interested parties can register for or listen to the call.

Conference Call Resources

AbCellera Biologics Earnings Headlines

AbCellera COO transitions to Chief Technology Officer
Collect $7k per month from Tesla’s SECRET dividend
There's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?
See More AbCellera Biologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AbCellera Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AbCellera Biologics and other key companies, straight to your email.

About AbCellera Biologics

AbCellera Biologics (NASDAQ:ABCL) builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

View AbCellera Biologics Profile

More Earnings Resources from MarketBeat